RxDoctor Payments Data

Jane Wardzinska, MD

Family Medicine · San Leandro, CANPI 1093732935

Payments from drug & device makers

$3,504in general payments, 2019–2025

Across 160 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$322
  • AstraZeneca$294
  • Boehringer Ingelheim$291
  • Bayer$260
  • Novo Nordisk$255
  • Johnson & Johnson$236
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$3,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,504 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$93,824
Medicare patients
198
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$49,402
XareltoRivaroxaban31$38,837
JardianceEmpagliflozin31$37,940
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$37,075
JanuviaSitagliptin Phosphate26$36,431
OzempicSemaglutide22$35,059
TrulicityDulaglutide16$18,583
Ambien CrZolpidem Tartrate11$13,663
TradjentaLinagliptin13$12,217
Breo ElliptaFluticasone/Vilanterol28$11,854
MyrbetriqMirabegron14$9,404
Gabapentin204$4,715
Albuterol Sulfate HfaAlbuterol Sulfate121$4,496
Xtampza ErOxycodone Myristate12$4,480
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$118$50,83157 claims
Boehringer IngelheimJardiance, Tradjenta$291$50,15744 claims
GSKTrelegy Ellipta, Breo Ellipta$104$48,92982 claims
Johnson & JohnsonXarelto$236$38,83731 claims
MerckJanuvia$322$36,43126 claims
Novo NordiskOzempic$255$35,05922 claims
Lilly USA, LLCTrulicity$97$18,58316 claims
Astellas Pharma US IncMyrbetriq$195$9,40414 claims
AstraZenecaSymbicort$294$3,40412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in San Leandro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →